Carrier in carrier: Catanionic vesicles based on amphiphilic cyclodextrins complexed with DNA as nanocarriers of doxorubicin

Alarcón, Liliana P.; Andrada, Heber E.; Olivera, Marı́a Eugenia; Silva, O. Fernando; Falcone, R. Darío

doi:10.1016/j.molliq.2022.119488

Cited by 7 publications

(1 citation statement)

References 72 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…This system showed great stability over a long period, small particle size, excellent drug loading capability, and strong, controlled release ability. These facts could be exploited to take advantage of EPR effects and decrease the side effects of DOX [ 132 ].…”

Section: Sirna Nanocarriersmentioning

confidence: 99%

Research Status and Prospect of Non-Viral Vectors Based on siRNA: A Review

Tong

Liu

Cao

et al. 2023

IJMS

View full text Add to dashboard Cite

Gene therapy has attracted much attention because of its unique mechanism of action, non-toxicity, and good tolerance, which can kill cancer cells without damaging healthy tissues. siRNA-based gene therapy can downregulate, enhance, or correct gene expression by introducing some nucleic acid into patient tissues. Routine treatment of hemophilia requires frequent intravenous injections of missing clotting protein. The high cost of combined therapy causes most patients to lack the best treatment resources. siRNA therapy has the potential of lasting treatment and even curing diseases. Compared with traditional surgery and chemotherapy, siRNA has fewer side effects and less damage to normal cells. The available therapies for degenerative diseases can only alleviate the symptoms of patients, while siRNA therapy drugs can upregulate gene expression, modify epigenetic changes, and stop the disease. In addition, siRNA also plays an important role in cardiovascular diseases, gastrointestinal diseases, and hepatitis B. However, free siRNA is easily degraded by nuclease and has a short half-life in the blood. Research has found that siRNA can be delivered to specific cells through appropriate vector selection and design to improve the therapeutic effect. The application of viral vectors is limited because of their high immunogenicity and low capacity, while non-viral vectors are widely used because of their low immunogenicity, low production cost, and high safety. This paper reviews the common non-viral vectors in recent years and introduces their advantages and disadvantages, as well as the latest application examples.

show abstract

Section: Sirna Nanocarriersmentioning

confidence: 99%

Research Status and Prospect of Non-Viral Vectors Based on siRNA: A Review

Tong

Liu

Cao

et al. 2023

IJMS

View full text Add to dashboard Cite

show abstract

Facile Fabrication of Dual‐Activatable Gastrointestinal‐Based Nanocarriers for Safe Delivery and Controlled Release of Methotrexate

Chen,

Nie,

Zhu

et al. 2023

ChemPlusChem

View full text Add to dashboard Cite

Colon cancer is emerging as one of the most common cancers worldwide, ranking in the top three in morbidity and mortality. Oral methotrexate (MTX) has been employed as a first‐line treatment for various cancers, such as colon, breast, and lung cancer. However, the complexity and particularity of the gastrointestinal microenvironment and the limitations of MTX itself, including severe adverse effects and instability, are the main obstacles to the safe delivery of MTX to colon tumor sites. Herein, an innovative oral administrated anticancer therapeutic MTX@Am7CD/SDS NPs equipped with both pH and temperature sensitivity, which could effectively prevent MTX@Am7CD/SDS NPs from being degraded in the acidic environment mimicking the stomach and small intestine, thus harboring the potential to accumulate at the site of colon lesions and further release intestinal drug under mild conditions. In cellular assays, compared with free MTX, MTX@Am7CD/SDS NPs showed a favorable tumor inhibition effect on three tumor cell lines, as well as excellent cell uptake and apoptosis‐inducing effect on SW480 cells. Therefore, this work provides a feasible solution for the safe use of MTX in the treatment of colon cancer and even other intestinal diseases.

show abstract

Investigation on the structural and dynamical properties of cationic, anionic, and catanionic niosomes as multifunctional controlled drug delivery system for cabozantinib

Poustforoosh

2024

Colloids and Surfaces A: Physicochemical and Engineering Aspect

View full text Add to dashboard Cite

Carrier in carrier: Catanionic vesicles based on amphiphilic cyclodextrins complexed with DNA as nanocarriers of doxorubicin

Cited by 7 publications

References 72 publications

Research Status and Prospect of Non-Viral Vectors Based on siRNA: A Review

Research Status and Prospect of Non-Viral Vectors Based on siRNA: A Review

Facile Fabrication of Dual‐Activatable Gastrointestinal‐Based Nanocarriers for Safe Delivery and Controlled Release of Methotrexate

Investigation on the structural and dynamical properties of cationic, anionic, and catanionic niosomes as multifunctional controlled drug delivery system for cabozantinib

Contact Info

Product

Resources

About